Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Progressive Multiple Sclerosis 2023-11-23
ASSESSMENT OF THE BRAIN DEPOSIT OF TAU 4R DETECTED BY BRAIN PET WITH 18F-PI2620 IN PROGRESSIVE SUPRANUCLEAR PALSY COMPARED TO CONTROLS WITHO… Ended

2023-503538-37-00 Progressive supranuclear palsy 2023-11-13
Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended

2023-503952-28-00 Steroid refractory Acute Graft versus host Disease 2023-11-13
A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethyl Fumarate in Friedreich Ataxia… Ended

2022-503016-16-00 Friedreich's Ataxia 2023-11-10
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy. DIAMOND STUDY Ended

2024-518017-26-00 metastatic HER2-positive breast cancer patients 2023-11-07
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended

2022-502789-26-01 Fibrostenotic Crohn’s Disease 2023-11-03
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended

2023-504273-21-00 Multiple Myeloma 2023-10-31
A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntingt… Ended

2023-504628-24-00 Huntington's Disease 2023-10-31
Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended

2022-502105-15-00 Systemic lupus erythematosus 2023-10-20
TIRACAN; Open label phase 2 basket trial with Atezolizumab and Tiragolumab in solid tumors Ended

2024-512616-21-00 HNSCC, metastatic deficient mismatch repair (dMMR)/MSI- 2023-10-18
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T… Ended

2023-508945-41-00 Hepatocellular Carcinoma 2023-10-11
Sentinel node detection with 99Tc albumin nanocolloid and indocianine green (ICG) in patients with epithelial ovarian cancer in early stages… Ended

2023-505667-37-00 Epithelial ovarian cancer in early stages. 2023-10-06
Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended

2024-514878-53-00 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk in 2023-10-04
Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease Ended

2022-502512-36-00 Progressive Fibrosing Interstitial Lung Diseases 2023-10-02
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 2023-09-28
Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate… Ended

2022-502188-39-00 Dermatitis atopic 2023-09-27
This is a phase 2 open label clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with… Ended

2024-512138-13-00 Recurrent ovarian cancer positive for MAGE-A4 in human 2023-09-27
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer. Ended

2022-502738-18-00 Metastatic Non-small Cell Lung Cancer 2023-09-15
CAT-Trial: CGRP monoclonal Antibody for Treatment of painful diabetic neuropathy: a double-blind, multicenter, placebo-controlled, internati… Ended

2022-500338-27-00 Painful diabetic polyneuropathy 2023-09-14
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended

2022-500100-21-01 Follicular lymphoma 2023-09-11
Inhibition of JAK enzymes in early stage joint inflammation Ended

2024-514026-23-00 preclinical phase of rheumatoid arthritis 2023-09-06
Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f… Ended

2024-515224-37-00 Patients with MSI-high or MMR-deficient stage III color 2023-08-29
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early… Ended

2024-512980-29-00 T1-T2N0 esophageal adenocarcinoma including gastroesoph 2023-08-28
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controll… Ended

2022-502038-23-00 Type 1 diabetes 2023-08-25